3 Questions: Using AI to accelerate the discovery and design of therapeutic drugs

Source Domain: news.mit.edu

Researchers at MIT, particularly James J. Collins, combine AI and quantitative modeling to develop engineered cells with new therapeutic properties aimed at combating diseases like Ebola, Zika, SARS-CoV-2, and antibiotic-resistant bacteria.
Collins’ interdisciplinary approach combines expertise from various fields to advance new diagnostics and therapeutics, leveraging collaborations across MIT and institutions like the Wyss Institute.
His work includes significant breakthroughs in developing new antibiotics using generative AI and deep learning, exemplified by the synthesis and testing of compounds like NG1 and DN1.
Collins collaborates with researchers across disciplines to accelerate the transition from computational predictions to validated new therapies, exemplified by projects like the MIT Jameel Clinic and Wyss Institute’s organs-on-chips technology.
He co-founded Phare Bio to advance promising antibiotic candidates toward clinical use and received a grant for creating 15 new antibiotics through generative AI, aiming to address the global threat of antibiotic resistance with novel, safe, and effective therapies.

3 Questions: Using AI to accelerate the discovery and design of therapeutic drugs | MIT News